Drugs / MNK6106
last change Jul 2020 re-read 2 minutes ago

MNK6106

Developed for
cirrhosis of liver · hepatic encephalopathy
Investigated by
Mallinckrodt

Trials 1 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03712280 Dec 2018 → Jul 2020 cirrhosis of liver, hepatic encephalopathy Mallinckrodt Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MNK6106 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03712280
Route Oral “1 gram tablet of MNK6106 for oral administration” NCT03712280